Loading
Latest filing published 26 Jun 2013 for Anthera Pharmaceuticals Inc, €40k.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
David E. Thompson discloses dealings in Anthera Pharmaceuticals Inc to SEC (Form 4). Over a trading history stretching from 3 January 2011 to 24 June 2013, the count stands at 4 filings.
The open-market record is one-sided, with 1 purchase worth €40k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 2 option exercises. So far in 2013, the count stands at 1 purchase and no sales.
The newest entry dates from 26 June 2013: an open-market purchase of €40k, in Anthera Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations